<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8CB3A3FE-C4A8-42E9-9244-671C2BC53767"><gtr:id>8CB3A3FE-C4A8-42E9-9244-671C2BC53767</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>T</gtr:otherNames><gtr:surname>Walton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190092710"><gtr:id>84FF35FA-834E-428F-84B3-F76DD28D8BC2</gtr:id><gtr:title>Tuberculosis Pharmacogenetics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190092710</gtr:grantReference><gtr:abstractText>There is evidence to suggest that inherited factors play a part in determining the response to treatment for TB. We will study whether variation in one gene NAT2, predicts treatment response in the largest study of its kind yet conducted.</gtr:abstractText><gtr:technicalSummary>This study aims to relate genetic variation in NAT2, a gene involved in the metabolism of isoniazid to response to treatment for tuberculosis. A fine density SNP assay will be designed to capture genetic variation in NAT2 and genotype and haplotype will be related to response to treatment measured by reversion of Elispot responses to TB antigens ESAT6 and CP10. There have been several studies on adverse effects related to NAT2 genotype but none has yet demonstrated effects on treatment outcome. The study will be conducted in TB case contacts treated with isoniazid alone.</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3142</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC Gambia Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8827281C-3EA2-4A3A-B945-27A5E5959992</gtr:id><gtr:impact>Visitors discussed research over posters and demonstrations at the MRC Gambia.

Increase knowledge locally of the work of the MRC and thus potential for dissemination of outputs locally and trial recruitment,</gtr:impact><gtr:outcomeId>ogSCzDatafC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asthma UK Centre for Applied Research. &amp;pound;2,000,000. Programme 2: How do we help people with asthma to treat and manage their symptoms, and maximise the benefits they get from treatment?</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>7C5753CF-A790-470C-9B46-E63621DB1B66</gtr:id><gtr:outcomeId>Yo6vLqpGohC</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1671212</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>e-cigaretes for smoking cessation in pregnancy- a randomised controlled trial</gtr:description><gtr:end>2021-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>70913EC5-B48B-4D74-8E84-1B45A4423338</gtr:id><gtr:outcomeId>58c79796ac4480.20483443</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2199373</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Programme Chronic viral hepatitis in ethnic minorities. Strategies to prevent the predicted increase in mortality. Co Applicant</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>63CD1453-6222-4D30-B59E-552BBB3598D6</gtr:id><gtr:outcomeId>odSya5DjAka0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>e-cigaretes for smoking cessation in pregnancy - HTA funded trial starting 2017</gtr:description><gtr:id>9A761F9D-5E8E-4A5B-A680-DEF19490B985</gtr:id><gtr:impact>Pending results of trial</gtr:impact><gtr:outcomeId>58c799320ffd72.09087969</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>e-cigaretes for smoking cessation in pregnancy</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>171 DNA samples typed by sequencing for NAT2 polymorphisms with clinical outcomes of treatment with isoniazid for latent TB.</gtr:description><gtr:id>00EF4AC9-77E7-48B7-BA2E-E3FA3947F8A1</gtr:id><gtr:impact>Used for a study on elispot reversion following isoniazid treatment. Paper is currently under preparation.</gtr:impact><gtr:outcomeId>JPvGmm7iRS7</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Database of West African NAT2 variants</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BDF3CCAD-E221-44A5-9A70-DA645563459F</gtr:id><gtr:title>Hepatitis B Virus Infection as a Neglected Tropical Disease</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d16cccce5e895a02e1d0e5c45995946a"><gtr:id>d16cccce5e895a02e1d0e5c45995946a</gtr:id><gtr:otherNames>O'Hara G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa95523df6b38.39207552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C93E2D8A-4E85-4185-8F2F-F4C0FFBD1140</gtr:id><gtr:title>Need to test impact of DNA-based risk scores</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f70975d8fed912eea789a8806c0f2a38"><gtr:id>f70975d8fed912eea789a8806c0f2a38</gtr:id><gtr:otherNames>Griffiths C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>56e1877c2efd07.77990936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F1F8226-C78E-493B-AB26-B24893EB468C</gtr:id><gtr:title>Urinary prostanoids in preschool wheeze.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6e36ec840873024b494320279d1426a"><gtr:id>f6e36ec840873024b494320279d1426a</gtr:id><gtr:otherNames>Grigg J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>58c78f3852c406.71561910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>106F9A9A-83A6-4121-A36D-25C82D9F0881</gtr:id><gtr:title>Effects of Air Pollution and the Introduction of the London Low Emission Zone on the Prevalence of Respiratory and Allergic Symptoms in Schoolchildren in East London: A Sequential Cross-Sectional Study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2f38603238347683cb740990a028cc8"><gtr:id>e2f38603238347683cb740990a028cc8</gtr:id><gtr:otherNames>Wood HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e18565004c64.60070511</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2658828-F6DB-4D13-BA68-459F35C251EB</gtr:id><gtr:title>Prevalence, determinants and clinical correlates of vitamin D deficiency in patients with Chronic Obstructive Pulmonary Disease in London, UK.</gtr:title><gtr:parentPublicationTitle>The Journal of steroid biochemistry and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e153d31b0ad14e6f7f06a2a5603f548f"><gtr:id>e153d31b0ad14e6f7f06a2a5603f548f</gtr:id><gtr:otherNames>Jolliffe DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0960-0760</gtr:issn><gtr:outcomeId>5aa9520ea659b6.67755460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80EBD069-073E-43C4-B1FF-A6C4895EFB85</gtr:id><gtr:title>Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution.</gtr:title><gtr:parentPublicationTitle>BMC evolutionary biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cda09f35d3ba99fe9f6c814453a7d0d"><gtr:id>6cda09f35d3ba99fe9f6c814453a7d0d</gtr:id><gtr:otherNames>Janha RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2148</gtr:issn><gtr:outcomeId>548583bde7eeb5.58134326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0AC59F6-2424-4299-96FD-FB700D9E9BCC</gtr:id><gtr:title>Mixed infection with cagA positive and cagA negative strains of Helicobacter pylori lowers disease burden in The Gambia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e6e30430ff7ff66b11c1a75d8cab2f"><gtr:id>d9e6e30430ff7ff66b11c1a75d8cab2f</gtr:id><gtr:otherNames>Secka O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16595_25_22140492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87CB9CF5-448D-401C-B3A2-7646F3030885</gtr:id><gtr:title>PCR-based genotyping of Helicobacter pylori of Gambian children and adults directly from biopsy specimens and bacterial cultures.</gtr:title><gtr:parentPublicationTitle>Gut pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e6e30430ff7ff66b11c1a75d8cab2f"><gtr:id>d9e6e30430ff7ff66b11c1a75d8cab2f</gtr:id><gtr:otherNames>Secka O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1757-4749</gtr:issn><gtr:outcomeId>DRb6Teepng2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63AD7BD2-94F0-435D-9641-2600CF4EF7A4</gtr:id><gtr:title>KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5aa9511ec47ca7.81477763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6BBD7C6-918B-470D-8171-939188DA0415</gtr:id><gtr:title>Single nucleotide polymorphisms in the vitamin D pathway associating with circulating concentrations of vitamin D metabolites and non-skeletal health outcomes: Review of genetic association studies.</gtr:title><gtr:parentPublicationTitle>The Journal of steroid biochemistry and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e153d31b0ad14e6f7f06a2a5603f548f"><gtr:id>e153d31b0ad14e6f7f06a2a5603f548f</gtr:id><gtr:otherNames>Jolliffe DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-0760</gtr:issn><gtr:outcomeId>56e18597baf7f0.20609606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0538DDA0-E6A6-432D-AC01-7B1BD4EAFF12</gtr:id><gtr:title>Molecular pathogenesis and early detection of hepatocellular carcinoma--perspectives from West Africa.</gtr:title><gtr:parentPublicationTitle>Cancer letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cc8502cee018caa2dfd8752dd14a92d"><gtr:id>0cc8502cee018caa2dfd8752dd14a92d</gtr:id><gtr:otherNames>Mendy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0304-3835</gtr:issn><gtr:outcomeId>Xuum7kRQMtF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D80873D7-C2CD-4CAB-B0E9-D223193B9D17</gtr:id><gtr:title>Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs).</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0dc8267178fe5eccc89abeb20ec15544"><gtr:id>0dc8267178fe5eccc89abeb20ec15544</gtr:id><gtr:otherNames>Martineau AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>56e18565285404.38277677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FAC5E14-8C60-4484-8203-25F38093B98B</gtr:id><gtr:title>Environmental and genetic determinants of vitamin D status among older adults in London, UK.</gtr:title><gtr:parentPublicationTitle>The Journal of steroid biochemistry and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e153d31b0ad14e6f7f06a2a5603f548f"><gtr:id>e153d31b0ad14e6f7f06a2a5603f548f</gtr:id><gtr:otherNames>Jolliffe DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-0760</gtr:issn><gtr:outcomeId>58c793c54ff980.24727589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96020E45-C190-43DB-9DC7-45E172C5A81E</gtr:id><gtr:title>Prevalence, determinants and clinical correlates of vitamin D deficiency in adults with inhaled corticosteroid-treated asthma in London, UK.</gtr:title><gtr:parentPublicationTitle>The Journal of steroid biochemistry and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e153d31b0ad14e6f7f06a2a5603f548f"><gtr:id>e153d31b0ad14e6f7f06a2a5603f548f</gtr:id><gtr:otherNames>Jolliffe DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0960-0760</gtr:issn><gtr:outcomeId>5aa950cf839814.18170100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCC905B7-6FB0-4671-B7C1-C6A9C15FEABE</gtr:id><gtr:title>Air pollution, ethnicity and telomere length in east London schoolchildren: An observational study.</gtr:title><gtr:parentPublicationTitle>Environment international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36afa0c1d1338733e375a40be83cfbab"><gtr:id>36afa0c1d1338733e375a40be83cfbab</gtr:id><gtr:otherNames>Walton RT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0160-4120</gtr:issn><gtr:outcomeId>58c790087d3bb0.09797308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>021E808B-DFE9-43F7-B36C-1715BCE263B8</gtr:id><gtr:title>HIV and chemokine binding to red blood cells--DARC matters.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36afa0c1d1338733e375a40be83cfbab"><gtr:id>36afa0c1d1338733e375a40be83cfbab</gtr:id><gtr:otherNames>Walton RT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>rz8n3SL8FK8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CCA24F9-E0E8-4531-87C6-9BEA5F5CA141</gtr:id><gtr:title>Gamification for health promotion: systematic review of behaviour change techniques in smartphone apps.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d764ab53151b5bbd5236fb0ef247bccf"><gtr:id>d764ab53151b5bbd5236fb0ef247bccf</gtr:id><gtr:otherNames>Edwards EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>58c7904a164871.13765139</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190092710</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>